FRA:GS71 • GB00BN7SWP63
The current stock price of GS71.DE is 24.93 EUR. In the past month the price increased by 12.1%. In the past year, price increased by 35.34%.
ChartMill assigns a technical rating of 10 / 10 to GS71.DE. When comparing the yearly performance of all stocks, GS71.DE is one of the better performing stocks in the market, outperforming 88.95% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to GS71.DE. There are concerns on the financial health of GS71.DE while its profitability can be described as average.
Over the last trailing twelve months GS71.DE reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 7.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.5% | ||
| ROA | 9.35% | ||
| ROE | 34.9% | ||
| Debt/Equity | 0.9 |
32 analysts have analysed GS71.DE and the average price target is 23.32 EUR. This implies a price decrease of -6.45% is expected in the next year compared to the current price of 24.93.
For the next year, analysts expect an EPS growth of 8.81% and a revenue growth 4.15% for GS71.DE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.45 | 196.87B | ||
| SAN | SANOFI | 9.45 | 196.725B | ||
| SNW | SANOFI | 9.63 | 196.652B | ||
| MRK | MERCK KGAA | 14.12 | 54.891B | ||
| UCB | UCB SA | 24.59 | 48.55B | ||
| UNC | UCB SA | 24.22 | 48.452B | ||
| 1BAYN | BAYER AG-REG | 7.9 | 40.255B | ||
| BAYN | BAYER AG-REG | 7.84 | 39.896B | ||
| IPN | IPSEN | 14.1 | 13.778B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.53 | 9.896B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
GSK PLC
980 Great West Road
Brentford MIDDLESEX GB
Employees: 68629
Phone: 442080475000
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
The current stock price of GS71.DE is 24.93 EUR. The price decreased by -0.44% in the last trading session.
GSK PLC (GS71.DE) has a dividend yield of 3.23%. The yearly dividend amount is currently 0.68.
GS71.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
GS71.DE stock is listed on the Frankfurt Stock Exchange exchange.
The Revenue of GSK PLC (GS71.DE) is expected to grow by 4.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
You can find the ownership structure of GSK PLC (GS71.DE) on the Ownership tab.